MYOCARDIAL REVASCULARIZATION IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION: PROBLEM STATEMENT
https://doi.org/10.15825/1995-1191-2013-2-156-163
Abstract
Outcomes of myocardium revascularization in patients with chronic left ventricular systolic dysfunction due to coronary artery disease are still unclear. The identification of dysfunctional myocardial with residual viability that can improve after revascularization are very important for further patient treatment. Hibernating myocardium can be identified by different methods and its presence and extent can predict functional and structural recovery after revascularization. New medical treatments and devices, have improved the prognosis of this patients and their use is supported by a number of clinical trials. The prognostic benefits of coronary revascularization for patients with chronic left ventricular dysfunction on optimal medical therapy and novel devices a randomized trial is still needed.
About the Author
A. B. Mironkov
City clinical hospital No 12 Department of healthcare of Moscow (Head – cand. of med. sci. A.V. Salikov), Moscow, Russian Federation
References
1. Adams Jr K.F., Fonarow G.C., Emerman C.L. Charac- teristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preli- minary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) // Am. Heart. J. 2005; 149: 209–216.
2. Gheorghiade M., Bonow R.O. Chronic heart failure in the United States: a manifestation of coronary artery di- sease // Circulation. 1998; 97: 282–289.
3. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Первые результаты национального эпидемиологического обследования – эпидемиологическое обследование больных ХСН в реальной практике (по обращаемос- ти) – ЭПОХА–О–ХСН // Сердечная недостаточность. 2003; 4 (3): 116–120.
4. Belenkov Y.N., Mareev V.Y., Ageev F.T. The first results of a national epidemiological study – epidemiological stu- dy of patients with CHF in real practice (referral) – the EPOHA-O-HSN study // Serdechnaya Nedostatochnost’. 2003; 4 (3): 116–120.
5. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Эпидемио- логическое исследование сердечной недостаточнос- ти: состояние вопроса // Сердечная недостаточность. 2002. 10: 57–58.
6. Belenkov Y.N., Mareev V.Y., Ageev F.T. Epidemiological study heart failure: problem statement // Serdechnaya Nedostatochnost’. 2002; 10: 57–58.
7. Horn H.R., Teichholz L.E., Cohn P.F., Herman M.V., Gorlin R. Augmentation of left ventricular contraction pattern in coronary artery disease by an inotropic cate- cholamine: The epinephrine ventriculogram // Circulati- on. 1974; 49: 1063–1071.
8. Helfant R.H., Pine R., Meister S.G., Feldman M.S., Trout R.G., Banka V.S. Nitroglycerin to unmask rever- sible asynergy: Correlation with post coronary bypass ventriculography // Circulation. 1974; 50: 108–113.
9. Wijns W., Vatner S.F., Camici P.G. Hibernating myocar- dium // N. Engl. J. Med. 1998; 339: 173–181.
10. Camici P.G., Prasad S.K., Rimoldi O.E. Stunning, hiber- nation and assessment of myocardial viability // Circula- tion. 2008; 117: 103–114.
11. Diamond G.A., Forrester J.S., de Luz P.L., Wyatt H.L., Swan H.J. Postextrasystolic potentiation of ischemic myocardium by atrial stimulation // Am. Heart. J. 1978; 95: 204–209.
12. Rahimtoola S.H. A perspective on the three large multi- center randomized clinical trials of coronary bypass sur-
13. gery for chronic stable angina // Circulation. 1985; 72:
14. V123–V135.
15. Uren N.G., Melin J.A., De Bruyne B., Wijns W., Baud-
16. huin T., Camici P.G. Relation between myocardial blood flow and the severity of coronary-artery stenosis // N. Engl. J. Med. 1994; 330: 1782–1788.
17. Tillisch J., Brunken R., Marshall R., Schwaiger M., Man- delkern M., Phelps M. Reversibility of cardiac wall-mo- tion abnormalities predicted by positron tomography // N. Engl. J. Med. 1986; 314: 884–888.
18. Schinkel A.F., Bax J.J., Poldermans D., Elhendy A., Ferrari R., Rahimtoola S.H. Hibernating myocardium: Diagnosis and patient outcomes // Curr. Probl. Cardiol. 2007; 32: 375–410.
19. Bateman T.M., Heller G.V., McGhie A.I., Friedman J.D., Case J.A., Bryngelson J.R. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: Comparison with ECG-gated Tc-99 m sestamibi SPECT // J. Nucl. Cardiol. 2006; 13: 24–33.
20. Ghosh N., Rimoldi O.E., Beanlands R.S., Camici P.G. Assessment of myocardial ischaemia and viability: Role of positron emission tomography // Eur. Heart. J. 2010. [E-pub ahead of print].
21. Marinho N.V., Keogh B.E., Costa D.C., Lammerst- ma A.A., Ell P.J., Camici P.G. Pathophysiology of chro- nic left ventricular dysfunction: New insights from the measurement of absolute myocardial blood flow and glu- cose utilization // Circulation 1996; 93: 737–744.
22. CASS. Coronary artery surgery study (CASS): A rando- mized trial of coronary artery bypass surgery: Survival data // Circulation. 1983; 68: 939–950.
23. Wijns W., Kolh P., Danchin N., Di Mario C., Falk V., Folliguet T. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) // Eur. Heart. J. 2010 [E-pub ahead of print].
24. McMurray J.J. Clinical practice: Systolic heart failure // N. Engl. J. Med. 2010; 362: 228–238.
25. Dickstein K., Cohen-Solal A., Filippatos G., McMur- ray J.J., Ponikowski P., Poole-Wilson P.A. ESC Guideli- nes for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: Developed in collabora- tion with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) // Eur. Heart. J. 2008; 29: 2388–2442.
26. Velazquez E.J., Lee K.L., O’Connor C.M., Oh J.K., Bo- now R.O., Pohost G.M. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial // J. Thorac. Cardiovasc. Surg. 2007; 134: 1540–1547.
27. Boden W.E., O’Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J. Optimal medical therapy with or without PCI for stable coronary disease // N. Engl. J. Med. 2007; 356: 1503–1516.
28. Hochman J.S., Lamas G.A., Buller C.E., Dzavik V., Rey- nolds H.R., Abramsky S.J. Coronary intervention for per- sistent occlusion after myocardial infarction // N. Engl. J. Med. 2006; 355: 2395–2407.
29. Frye R.L., August P., Brooks M.M., Hardison R.M., Kel- sey S.F., MacGregor J.M. A randomized trial of thera- pies for type 2 diabetes and coronary artery disease // N. Engl. J. Med. 2009; 360: 2503–2515.
30. Erne P., Schoenenberger A.W., Burckhardt D., Zuber M., Kiowski W., Buser P.T. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarc- tion: The SWISSI II randomized controlled trial. JAMA. 2007; 297: 1985–1991.
31. Alderman E.L., Bourassa M.G., Cohen L.S., Davis K.B., Kaiser G.G., Killip T. Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Arte- ry Surgery Study // Circulation. 1990; 82: 1629–1646.
32. Pitt B., Waters D., Brown W.V., van Boven A.J., Schwartz L., Title L.M. Aggressive lipid-lowering thera- py compared with angioplasty in stable coronary artery disease: Atorvastatin versus Revascularization Treat- ment Investigators // N. Engl. J. Med. 1999; 341: 70–76.
33. Shaw L.J., Berman D.S., Maron D.J., Mancini G.B., Hayes S.W., Hartigan P.M. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the Clinical Out- comes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy // Circu- lation. 2008; 117: 1283–1291.
34. Chaitman B.R., Hardison R.M., Adler D., Gebhart S., Grogan M., Ocampo S. The Bypass Angioplasty Revas- cularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: Impact of treatment strategy on cardiac mortality and myocardial infarction // Circulation. 2009; 120: 2529–2540.
35. Cantor W.J., Baptista S.B., Srinivas V.S., Pearte C.A., Menon V., Sadowski Z. Impact of stress testing before percutaneous coronary intervention or medical manage- ment on outcomes of patients with persistent total oc- clusion after myocardial infarction: Analysis from the occluded artery trial // Am. Heart. J. 2009; 157: 666–672.
36. Allman K.C., Shaw L.J., Hachamovitch R., Udelson J.E. Myocardial viability testing and impact of revasculari- zation on prognosis in patients with coronary artery di- sease and left ventricular dysfunction: A meta-analysis // J. Am. Coll. Cardiol. 2002; 39: 1151–1158.
37. Tarakji K.G., Brunken R., McCarthy P.M., Al-Cheka- kie M.O., Abdel-Latif A., Pothier C.E. Myocardial viabi- lity testing and the effectof early intervention in patients with advanced left ventricular systolic dysfunction // Circulation. 2006; 113: 230–237.
38. PackerM.,CoatsA.J.,FowlerM.B.,KatusH.A.,KrumH., Mohacsi P. Effect of carvedilol on survival in severe chro- nic heart failure // N. Engl. J. Med. 2001; 344: 1651–1658.
39. Ellenbogen K.A., Wood M.A., Klein H.U. Why should we care about CARE-HF? // J. Am. Coll Cardiol. 2005; 46: 2199–2203.
40. Sata Y., Krum H. The future of pharmacological therapy for heart failure // Circ. J. 2010; 74: 809–817.
41. Fox K., Garcia M.A., Ardissino D., Buszman P., Cami- ci P.G., Crea F. Guidelines on the management of stable angina pectoris: Executive summary: The Task Force on the Management of Stable Angina Pectoris of the Euro-
42. pean Society of Cardiology // Eur. Heart. J. 2006; 27:
43. –1381.
44. Kruk M., Buller C.E., Tcheng J.E., Dzavik V., Menon V.,
45. Mancini G.B. Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Arte- ry Trial [OAT]) // Am. J. Cardiol. 2010; 105: 10–16.
46. Dzavik V., Buller C.E., Lamas G.A., Rankin J.M., Manci- ni G.B., Cantor W.J. Randomized trial of percutaneous co- ronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: The Total Occlusion Study of Canada (TOSCA)-2 trial // Circulation. 2006; 114: 2449–2457.
47. Kirschbaum S.W., Springeling T., Boersma E., Moel- ker A., van der Giessen W.J., Serruys P.W. Complete percutaneous revascularization for multivessel disease in patients with impaired left ventricular function: Pre- and post-procedural evaluation by cardiac magnetic resonance imaging JACC // Cardiovasc Interv. 2010; 3: 392–400.
48. Cleland J.G., Pennell D.J., Ray S.G., Coats A.J., Macfar- lane P.W., Murray G.D. Myocardial viability as a deter- minant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): Rando- mised controlled trial // Lancet. 2003; 362: 14–21.
49. Beanlands R.S., Nichol G., Huszti E., Humen D., Raci- ne N., Freeman M. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and su- spected coronary disease: A randomized, controlled trial (PARR-2) // J. Am. Coll. Cardiol. 2007; 50: 2002–2012.
50. Abraham A., Nichol G., Williams K.A., Guo A., deKemp R.A., Garrard L. 18F-FDG PET imaging of myocardial viability in an experienced center with ac- cess to 18F-FDG and integration with clinical manage- ment teams: The Ottawa-FIVE substudy of the PARR 2 trial // J. Nucl. Med. 2010; 51: 567–574.
51. D’Egidio G., Nichol G., Williams K.A., Guo A., Gar- rard L., deKemp R. Increasing benefit from revasculari- zation is associated with increasing amounts of myocar- dial hibernation: A substudy of the PARR-2 trial // JACC Cardiovasc. Imaging. 2009; 2: 1060–1068.
52. Jones R.H., Velazquez E.J., Michler R.E., Sopko G., Oh J.K., O’Connor C.M. Coronary bypass surgery with or without surgical ventricular reconstruction // N. Engl. J. Med. 2009; 360: 1705–1717.
53. Serruys P.W., Morice M.C., Kappetein A.P., Colombo A., Holmes D.R., Mack M.J. Percutaneous coronary interven- tion versus coronary-artery bypass grafting for severe coro- nary artery disease // N. Engl. J. Med. 2009; 360: 961–972.
54. Cleland J.G., Daubert J.C., Erdmann E., Freemantle N., Gras D., Kappenberger L. The effect of cardiac resyn- chronization on morbidity and mortality in heart failu- re // N. Engl. J. Med. 2005; 352: 1539–1549.
55. Moss A.J., Zareba W., Hall W.J., Klein H., Wilber D.J., Cannom D.S. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejec- tion fraction // N. Engl. J. Med. 2002; 346: 877–883.
56. Moss A.J. What we have learned from the family of mul- ticenter automatic defibrillator implantation trials // Circ. J. 2010; 74: 1038–1041.
Review
For citations:
Mironkov A.B. MYOCARDIAL REVASCULARIZATION IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION: PROBLEM STATEMENT. Russian Journal of Transplantology and Artificial Organs. 2013;15(2):156-163. (In Russ.) https://doi.org/10.15825/1995-1191-2013-2-156-163
Views:
1459
Email this article 